12-Month Lobbying Summary - In-house Corporation

• Subject matter details in previous versions

  Details Regarding the Identified Subject Matter

  Subject matters	Details	Categories
  Subject matters were not required to be associated with subject matter details when this content was submitted	Economic Growth Initiatives as it relates to clinical trials investment, life sciences industry.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Federal budget with respect to science and technology in the healthcare sector, specifically with respect to medical technology and devices.	Legislative Proposal, Bill or Resolution
  Subject matters were not required to be associated with subject matter details when this content was submitted	Federal guidelines with respect to procurement of medical technologies and adoption of innovation in the healthcare industry	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Federal healthcare strategy with respect to COVID-19 as well as Public Health Strategies.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Federal healthcare strategy with respect to patient safety, medication errors, healthcare worker safety, infection and disease prevention, and laboratory diagnostic testing.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Federal science & technology strategy with respect to medical technology, specifically focusing on accelerating innovation to improve health and economic outcomes.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Federal science & technology strategy, focusing on promoting collaboration with respect to clinical and scientific research in the healthcare industry.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Innovation Agenda - as it relates to the Life Science Industry and the Federal Initiative lead by Innovation, Science, Economic Development	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Medical Devices Bureau, Biologics and Genetic Therapies Directorate as it relates to policies affecting the review and approval of submissions.	Policies or Program

  Subject matters in previous versions

  • Budget
  • Defence
  • Employment and Training
  • Government Procurement
  • Health
  • Industry
  • Intellectual Property
  • Labour
  • Privacy and Access to Information
  • Research and Development
  • Science and Technology

  Subject matters added through a communication report:

  • Infrastructure
  • Taxation and Finance

Government Institutions

• Competition Bureau Canada (COBU)
• Federal Economic Development Agency for Southern Ontario (FedDev)
• Finance Canada (FIN)
• Global Affairs Canada (GAC)
• Health Canada (HC)
• House of Commons
• Innovation, Science and Economic Development Canada (ISED)
• Intergovernmental Affairs Secretariat (IGA)
• Justice Canada (JC)
• National Defence (DND)
• Office of the Commissioner of Lobbying (OCL)
• Office of the Privacy Commissioner of Canada (OPC)
• Prime Minister's Office (PMO)
• Public Health Agency of Canada (PHAC)
• Public Services and Procurement Canada (PSPC)
• Senate of Canada
• Shared Services Canada (SSC)
• Treasury Board Of Canada Secretariat (TBS)

Communication techniques

Communication techniques that have been used or are expected to be used in the course of the undertaking:

• Grass-roots communication
• Oral communication
• Written communication

Senior Officers whose lobbying activities represent less than 20% of their Duties

• Vito Ciciretto, President & CEO | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

• Sebastien Beauchamp, Vice President, Government Relations | No public offices held

• Lobbyists in previous versions

  Senior Officers whose lobbying activities represent less than 20% of their Duties

  • Brendon Lalonde, Vice President- Business Development | No public offices held